The Children’s Hospital University of Illinois
No posts currently available to show
Northwestern University – Ann and Robert H. Lurie Children’s Hospital of Chicago
No posts currently available to show
Medical College of Wisconsin – Children’s Hospital of Wisconsin
No posts currently available to show
Rush University Children’s Hospital
No posts currently available to show
University of Chicago – Comer Children’s Hospital
No posts currently available to show
University of Iowa – Stead Family Children’s Hospital
No posts currently available to show
University of Minnesota – Masonic Children’s Hospital
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
This is a phase II trial using a non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen with modifications based on factors including diagnosis, disease status, and prior treatment. Single or double unit selected according to current University of Minnesota umbilical cord blood graft selection algorithm.
January 15, 2021Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic
This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a haploidentical hematopoietic cell transplant (haplo-HCT) in persons with diagnosis of hematologic malignancy. Conditioning will consists of fludarabine, cyclophosphamide, …
January 15, 2021- More Hodgkin Lymphoma - University of Minnesota – Masonic Children’s Hospital posts
University of Wisconsin – American Family Children’s Hospital
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk solid tumors.
August 25, 2020Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (CLOVER-2)
The study evaluates CLR 131 in children and adolescents with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment options with curative potential.
August 25, 2020- More Hodgkin Lymphoma - University of Wisconsin – American Family Children’s Hospital posts